Health ministry questions reliability of vasculitis drug approval data
Tavneos was launched in Japan in 2022 after being approved by the ministry. Its package insert listed liver dysfunction as a serious side effect.
We haven't written up this one. Japan Times has the full story — the link below goes straight to it.